SZSE Ticker: 000403

Southern Shuanglin Bio-Pharmacy Co., Ltd

南方双林生物制药股份有限公司

双林生物

SLBIO

Listing Date: 1996-06-28

Board: Main Board - A Shares

Industry Classification: Manufacturing

15 Companies Earned Recommended Ratings Updating CFi.CN

15 Companies Earned Recommended Ratings Updating CFi.CN

15 Companies Get Recommended Ratings Updating CFi.CN

15 Companies Earned Recommended Ratings Updating CFi.CN

Perrin Bio (000403): Perrin Bio: Record Form of Investor Relations Activities on May 5, 2022 CFi.CN Zhongcai Network

Pyrin Biotech has been surveyed by 84 institutions: the company has no clear plan for equity cooperation with Xinjiang Deyuan (with survey questions and answers)

Pyrin Bio has been investigated by 84 institutions: the company's main business is the research, development, production and sales of blood products (with survey questions and answers)

Perrin Bio (000403): Perrin Bio: Record Form of Investor Relations Activities on May 5, 2022 CFi.CN Zhongcai Network

13 companies receive recommendation ratings Updating CFi.CN Zhongcai Network

13 companies receive recommendation ratings Updating CFi.CN Zhongcai Network

13 companies receive recommendation ratings Updating CFi.CN Zhongcai Network

24 stocks released after-hours performance forecast-Update-CFi.CN Zhongcai Network

[China Securities Pre-market] "Xiaohua" plans to send 9 yuan per 10 yuan; "Chinese Medicine Mao" has a record high net profit last year; Jiu'an Medical received another 2.6 billion yuan from the US ACC_Oriental Fortune Network

A new outlet for autonomous driving! The core market segment may take off 14 shares have been preempted! 7 shares recently announced that the high-growth power IDM leader in the first quarter has attracted market attention (with shares)

A new outlet for autonomous driving! The core market segment may take off, and 14 shares have been preempted! 7 shares recently announced high growth in the first quarter, and the power IDM leader has attracted market attention (with shares)

Pylin Bio's net profit in 2021 is 391 million, a year-on-year increase of 110.27%

The first quarter of 2022 is expected to be a net profit of 95.88 million-124 million yuan, an increase of 70%-120% year-on-year, and the growth of raw plasma collection.

A-share Toutiao listed company (4.16) Stock Financial Industry

Perrin Biotech (000403.SZ) issued pre-earnings and expects first-quarter net profit of 96 million to 124 million yuan, a year-on-year increase of 70% to 120%_Stock Information_Market Gold Online

Perrin Biotech (000403.SZ)'s first-quarter net profit is expected to increase by 70%-120%_Stock Information_Market Gold Online

Investment hedging guide: Minhe shares pre-lost more than 170 million yuan in the first quarter, Taier shares expected a year-on-year decrease of more than 85.26% in net profit in the first quarter, and Leon Micro shareholders plan to reduce their holdings by no more than 3% of the company's shares

Want to see more data? Registered subscribers can see all the data.